Collaborations & Alliances

Ionis Licenses New Kidney Disease Drug to AstraZeneca

Becomes second drug to enter development under strategic collaboration with AstraZeneca

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ionis Pharmaceuticals has licensed its Generation 2.5 IONIS-AZ5-2.5 to AstraZeneca. IONIS-AZ5-2.5 is an antisense drug designed to inhibit an undisclosed target to treat a genetically associated form of kidney disease. AstraZeneca will be responsible for developing and commercializing IONIS-AZ5-2.5.   Ionis will receive $30 million upfront and is eligible to receive as much as $300 million in additional development and regulatory milestones, as well as royalties on sales.   “This is th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters